share_log

Benchmark Initiates Coverage On CytoMed Therapeutics With Speculative Buy Rating, Announces Price Target of $5

Benchmark Initiates Coverage On CytoMed Therapeutics With Speculative Buy Rating, Announces Price Target of $5

Benchmark以投機性買入評級啓動對CytoMed Therapeutics的報道,宣佈目標股價爲5美元
Benzinga ·  2023/07/21 06:51

Benchmark analyst Bruce Jackson initiates coverage on CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy rating and announces Price Target of $5.

基準分析師布魯斯·傑克遜以投機性買入評級開始對CytoMed Therapeutics(納斯達克股票代碼:GDTC)進行報道,並宣佈目標股價爲5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論